Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of ...

The last time I wrote about 4D Molecular Therapeutics, Inc. (FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In this ...

5 analysts have expressed a variety of opinions on 4D Molecular Therapeutics (NASDAQ:FDMT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...

SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...

In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent ...

4 analysts have shared their evaluations of 4D Molecular Therapeutics (NASDAQ:FDMT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 vector invented by 4DMT for one ...